Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

TMB-H 1Lymphoma, Extranodal NK-T-Cell 1Liver Neoplasms 1

Interventions

Specimen Handling 613pembrolizumab 563Magnetic Resonance Spectroscopy 536Carboplatin 425Cisplatin 375Cyclophosphamide 373Biopsy 357Paclitaxel 306Gemcitabine 303Nivolumab 300Radiotherapy 260Bevacizumab 234Dexamethasone 209fludarabine 205Docetaxel 187durvalumab 182atezolizumab 173Oxaliplatin 172venetoclax 168Fluorouracil 166Rituximab 165Pemetrexed 163Capecitabine 158Doxorubicin 157Radiation 155Radiosurgery 148Etoposide 137Leucovorin 133Ipilimumab 133Lenalidomide 131

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × IMC-001 × 90 days × Clear all
NCT04196465 2026-05-22

NeoChance

Asan Medical Center

Phase 2 Active not recruiting
48 enrolled
Gastrointestinal

Liver Neoplasms

NCT04414163 2026-04-24

A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

ImmuneOncia Therapeutics Inc.

Phase 2 Active not recruiting
23 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT06365840 2026-04-17

TMB-H

ImmuneOncia Therapeutics Inc.

Phase 2 Recruiting
30 enrolled
Other solid neoplasm

TMB-H

Data powered by HemOnc (CC BY 4.0) Colophon âš¡